GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Cyclically Adjusted PB Ratio: (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
78 GF Score
Price ₹2,902.20
GF Value ₹2,726.38
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GlaxoSmithKline Pharmaceuticals  (NSE:GLAXO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Cyclically Adjusted PB Ratio Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 17.09 14.86

GlaxoSmithKline Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 16.36 0.00 14.86 0.00

NSE:GLAXO vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


NSE:GLAXO
78GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, GlaxoSmithKline Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

GlaxoSmithKline Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201212 118.463 83.774 236.655
201312 117.454 91.425 215.005
201503 144.273 97.163 248.502
201603 128.877 102.518 210.387
201703 118.464 105.196 188.465
201706 0.000 107.109 0.000
201803 121.444 109.786 185.128
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 126.314 118.202 178.843
201906 0.000 120.880 0.000
201909 138.463 123.175 188.129
201912 0.000 126.235 0.000
202003 107.470 124.705 144.227
202006 0.000 127.000 0.000
202009 78.348 130.118 100.771
202012 0.000 130.889 0.000
202103 87.261 131.771 110.827
202106 0.000 134.084 0.000
202109 76.467 135.847 94.204
202112 0.000 138.161 0.000
202203 157.194 138.822 189.506
202206 0.000 142.347 0.000
202209 85.882 144.661 99.356
202212 0.000 145.763 0.000
202303 102.787 146.865 117.129
202306 0.000 150.280 0.000
202309 90.879 151.492 100.396
202312 0.000 152.924 0.000
202403 104.934 153.035 114.755
202406 0.000 155.789 0.000
202409 98.739 157.882 104.665
202412 0.000 158.323 0.000
202503 115.185 157.552 122.354
202506 0.000 159.755 0.000
202509 100.805 162.289 103.953
202512 0.000 163.281 0.000
202603 133.845 164.272 136.358
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,902.20 is trading 6.4% above its estimated GF Value™ of ₹2,726.38. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLAXO:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹2,726.38 vs. price of ₹2,902.20 (6.4% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
78GF Score

Get the complete analysis for NSE:GLAXO

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,902.20
Price
₹2,726.38
GF Value